Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kamilla Danebod

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Ugeskrift for Laeger|August 24, 2023
Carina Kirstine Klarskov, Kamilla Danebod, Louise Schouborg Brinth, et al.
The Journal of Pediatrics|July 1, 2008
Thymus size at 6 months of age and subsequent child mortalityMay-Lill Garly, Sisse Lecanda Trautner, Charlotte Marx, et al.
Therapeutic Advances in Musculoskeletal Disease|December 29, 2025
Safety outcomes in 2132 Danish patients with inflammatory arthritis treated with biosimilar infliximab (GP1111) in routine careHafsah Nabi, Kasper Yde Jensen, Rasmus Westermann, et al.
Annals of the Rheumatic Diseases|April 30, 2021
Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trialHafsah Nabi, Stylianos Georgiadis, Anne Gitte Loft, et al.
RMD Open|November 23, 2022
Nationwide, large-scale implementation of an online system for remote entry of patient-reported outcomes in rheumatology: characteristics of users and non-users and time to first entryBente Glintborg, Dorte Vendelbo Jensen, Lene Terslev, et al.
RMD Open|January 6, 2021
Self-protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: results and predictors in more than 12 000 patients with inflammatory rheumatic diseases followed in the Danish DANBIO registryBente Glintborg, Dorte Vendelbo Jensen, Sara Engel, et al.
The Journal of Rheumatology|June 15, 2022
Long-term Behavioral Changes During the COVID-19 Pandemic and Impact of Vaccination in Patients With Inflammatory Rheumatic DiseasesBente Glintborg, Dorte Vendelbo Jensen, Lene Terslev, et al.
Rheumatology (Oxford, England)|June 19, 2021
Impact of the COVID-19 pandemic on treat-to-target strategies and physical consultations in >7000 patients with inflammatory arthritisBente Glintborg, Dorte Vendelbo Jensen, Lene Terslev, et al.
RMD Open|November 23, 2022
Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registryHafsah Nabi, Oliver Hendricks, Dorte Vendelbo Jensen, et al.
Annals of the Rheumatic Diseases|November 7, 2018
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registryBente Glintborg, Anne Gitte Loft, Emina Omerovic, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Ugeskrift for Laeger|August 24, 2023
Carina Kirstine Klarskov, Kamilla Danebod, Louise Schouborg Brinth, et al.
The Journal of Pediatrics|July 1, 2008
Thymus size at 6 months of age and subsequent child mortalityMay-Lill Garly, Sisse Lecanda Trautner, Charlotte Marx, et al.
Therapeutic Advances in Musculoskeletal Disease|December 29, 2025
Safety outcomes in 2132 Danish patients with inflammatory arthritis treated with biosimilar infliximab (GP1111) in routine careHafsah Nabi, Kasper Yde Jensen, Rasmus Westermann, et al.
Annals of the Rheumatic Diseases|April 30, 2021
Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trialHafsah Nabi, Stylianos Georgiadis, Anne Gitte Loft, et al.
RMD Open|November 23, 2022
Nationwide, large-scale implementation of an online system for remote entry of patient-reported outcomes in rheumatology: characteristics of users and non-users and time to first entryBente Glintborg, Dorte Vendelbo Jensen, Lene Terslev, et al.
RMD Open|January 6, 2021
Self-protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: results and predictors in more than 12 000 patients with inflammatory rheumatic diseases followed in the Danish DANBIO registryBente Glintborg, Dorte Vendelbo Jensen, Sara Engel, et al.
The Journal of Rheumatology|June 15, 2022
Long-term Behavioral Changes During the COVID-19 Pandemic and Impact of Vaccination in Patients With Inflammatory Rheumatic DiseasesBente Glintborg, Dorte Vendelbo Jensen, Lene Terslev, et al.
Rheumatology (Oxford, England)|June 19, 2021
Impact of the COVID-19 pandemic on treat-to-target strategies and physical consultations in >7000 patients with inflammatory arthritisBente Glintborg, Dorte Vendelbo Jensen, Lene Terslev, et al.
RMD Open|November 23, 2022
Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registryHafsah Nabi, Oliver Hendricks, Dorte Vendelbo Jensen, et al.
Annals of the Rheumatic Diseases|November 7, 2018
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registryBente Glintborg, Anne Gitte Loft, Emina Omerovic, et al.
Pageof 1